U.S. health regulator approves Iroko's pain drug
Oct 18 (Reuters) - Privately held Iroko Pharmaceuticals Inc said the U.S. Food and Drug Administration approved its capsules to treat mild to moderate acute pain in adults.
The drug, Zorvolex, is approved at a dosage strength that is 20 percent lower than currently available treatments, the company said in a statement.
The current available treatments have higher dosages increasing the risk of serious adverse events including strokes, gastrointestinal ulcers and acute renal failures, the company said.
The drug comes under the category of nonsteroidal anti-inflammatory drugs (NSAID), which are medicines that relieve pain including swelling, stiffness and inflammation.
A late-stage study of the drug showed that patients showed significant pain relief compared with patients on a placebo.
Iroko had filed for an initial public offering of $145 million in June 2013 but withdrew its plans, saying that the timing of the offering might not be in its best interests.
- Tesla says in talks with BMW over car batteries, parts
- Hagel, under pressure, resigns as U.S. defense secretary |
- Missouri grand jury makes decision in fatal shooting of black teen |
- Actor Dwight Henry eyed in New Orleans killing after arrest for theft
- Iran nuclear talks extended seven months after failing to meet deadline |
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video